Literature DB >> 16678994

Establishment of a peritoneal malignancy treatment centre in the United Kingdom.

Brendan J Moran1.   

Abstract

The development, funding and early treatment outcomes of a centre for the assessment and management of a rare tumour is outlined. Central government funding, as obtained from the National Health Service in this instance, is optimal to allow service development and outcome assessment. The initiation and development of a new specialized service is probably best approached by focusing on a condition that is rare, with a reasonable number of cases and good outcomes. This report reviews an experience focusing on "pseudomyxoma peritonei of appendiceal origin" with an estimated annual incidence of one per million per year. The experience of a colorectal unit in structuring a national centre is reviewed in an attempt to document the development, funding and resources required to initiate and maintain a unit. The surgical skill, with its associated learning curve, and some early results of treatment are presented with the hope that such an experience may be of help to others.

Entities:  

Mesh:

Year:  2006        PMID: 16678994     DOI: 10.1016/j.ejso.2006.03.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  10 in total

1.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

Review 2.  Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-08

3.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

Authors:  V López-López; P A Cascales-Campos; E Gil; J Arevalo; A Gonzalez; J Gil; F C Muñoz-Casares; J T Melero; P Barrios; R Morales; I Ramos; G Ortega; B Camps; L González-Bayón; P Bretcha-Boix; J Farré-Alegre; S González-Moreno; P Parrilla
Journal:  Clin Transl Oncol       Date:  2017-08-10       Impact factor: 3.405

4.  A new standard of care for the management of peritoneal surface malignancy.

Authors:  F Mohamed; T Cecil; B Moran; P Sugarbaker
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

5.  On or in the liver? Two cases with diffuse pseudomyxoma peritonei and synchronous hepatic pathology.

Authors:  H Youssef; B J Moran
Journal:  Tech Coloproctol       Date:  2011-01-20       Impact factor: 3.781

6.  The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases.

Authors:  Aditi Bhatt; Sanket Mehta; Ramakrishnan Ayloor Seshadri; Kayomarz Sethna; Shabber Zaveri; Firoz Rajan; Vikas Mahajan; Shivendra Singh; E Hemanth Raj; Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2016-02-02

Review 7.  Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective.

Authors:  Priya Mistry; Faheez Mohamed; Sanjeev Dayal; Tom D Cecil; Brendan J Moran
Journal:  Eur J Hosp Pharm       Date:  2016-04-05

8.  Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico.

Authors:  Horacio N López-Basave; Flavia Morales-Vásquez; J M Ruiz Molina; Aaron González-Enciso; Silvio A Namendys-Silva; Juan M Medina Castro; Gonzalo Montalvo-Esquivel; Angel Herrera-Gómez; Jaime G De la Garza Salazar
Journal:  ISRN Oncol       Date:  2011-08-03

9.  Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study.

Authors:  Dušan Klos; Juraj Riško; Martin Loveček; Pavel Skalický; Ivana Svobodová; Denisa Krejčí; Bohuslav Melichar; Beatrice Mohelníková-Duchoňová; Radmila Lemstrová
Journal:  World J Surg Oncol       Date:  2019-11-06       Impact factor: 2.754

10.  A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.

Authors:  A L Farquharson; N Pranesh; G Witham; R Swindell; M B Taylor; A G Renehan; S Rout; M S Wilson; S T O'Dwyer; M P Saunders
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.